Operator

Good morning, and welcome to the First Quarter 2026 Lifeward Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the conference over to Almog Adar, CFO of Lifeward. Please go ahead.

Almog Adar
Chief Financial Officer

Thank you, Drew, and thanks, everyone, who has joined us on the call today. My name is Almog Adar, I'm Lifeward' Chief Financial Officer. And with me on today's call is our President and Chief Executive Officer, Mark Grant.

Earlier this morning, Lifeward issued a press release detailing the financial results for the first quarter ended March 31, 2026. I would ask you to review the full text of our forward-looking statements from the press release. We anticipate making projections during this call, and actual results could differ materially due to several factors, including those outlined in our latest filings with the SEC.

With that, I will turn the call over to Mark.

William Grant
President, CEO & Director

Thank you, Almog, and thank you for everybody for joining us today. The first quarter of 2026 marked an important strategic milestone for Lifeward as we successfully completed the acquisition of Oratech. We believe this transaction significantly strengthens Lifeward's position as a diversified biomedical innovation company while reinforcing our focus on neurorehabilitation and our path toward profitability. We believe this was a highly strategic and capital-efficient transaction for Lifeward shareholders.

Through the equity-based acquisition of Oratech, we gained access to the protein oral delivery